Skip to content

Prediction of Acute Rejection in Renal Transplant

Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00205257
Enrollment
Unknown
Registered
2005-09-20
Start date
2001-09-30
Completion date
2007-02-28
Last updated
2015-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant

Brief summary

Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.

Interventions

None listed

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* One hundred subjects undergoing kidney biopsy for suspected rejection * Forty subjects that have stable graft function with normal level of blood creatinine (No biopsy is needed at the time of sample collection).

Exclusion criteria

* Subjects under the age of 18 * Gender of potential subjects male or female * Age Limits greater than 18 years of age

Design outcomes

Primary

MeasureTime frame
kidney biopsy pathology1 year

Secondary

MeasureTime frame
urinary chemokines1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026